


Searching News Database: MetaStat
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 6 Feb 2026
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
HSMN NewsFeed - 9 Sep 2025
ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001
ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001
HSMN NewsFeed - 3 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
HSMN NewsFeed - 21 Jun 2023
Aethlon Medical Announces Investigation of the Hemopurifier(R) for Use in Organ Transplantation
Aethlon Medical Announces Investigation of the Hemopurifier(R) for Use in Organ Transplantation
HSMN NewsFeed - 13 Jun 2023
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian(R) MRI-Guided Radiation Therapy System
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian(R) MRI-Guided Radiation Therapy System
HSMN NewsFeed - 22 Mar 2023
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
HSMN NewsFeed - 23 Aug 2022
VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
HSMN NewsFeed - 9 Jun 2022
VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
HSMN NewsFeed - 27 May 2022
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
HSMN NewsFeed - 7 Feb 2022
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer
HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
HSMN NewsFeed - 21 Sep 2021
Dr. Milan Radovich, Ph.D., Joins Caris Life Sciences as Chief Precision Medicine Officer
Dr. Milan Radovich, Ph.D., Joins Caris Life Sciences as Chief Precision Medicine Officer
HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
HSMN NewsFeed - 17 Jun 2021
Elekta radiotherapy system designed for changing cancer landscape now available for U.S. patients
Elekta radiotherapy system designed for changing cancer landscape now available for U.S. patients
HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 3 Nov 2020
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
HSMN NewsFeed - 26 Oct 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
HSMN NewsFeed - 23 Jul 2020
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
HSMN NewsFeed - 7 Jul 2020
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
HSMN NewsFeed - 23 Jun 2020
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
HSMN NewsFeed - 11 Jun 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
HSMN NewsFeed - 29 May 2020
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
HSMN NewsFeed - 27 May 2020
Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian Linac
Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian Linac
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 12 Mar 2020
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
HSMN NewsFeed - 13 Feb 2020
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
HSMN NewsFeed - 5 Feb 2020
Ichnos Expands Leadership Team With Appointment Of Gabriela Gruia, M.D. As Chief Development Officer
Ichnos Expands Leadership Team With Appointment Of Gabriela Gruia, M.D. As Chief Development Officer
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 13 Jan 2020
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
HSMN NewsFeed - 30 Dec 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
HSMN NewsFeed - 26 Nov 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
HSMN NewsFeed - 19 Nov 2019
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
HSMN NewsFeed - 2 Sep 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
HSMN NewsFeed - 15 Jul 2019
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
HSMN NewsFeed - 29 Apr 2019
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
HSMN NewsFeed - 22 Apr 2019
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
HSMN NewsFeed - 28 Nov 2018
Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron(TM) from GE Healthcare
Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron(TM) from GE Healthcare
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 12 Nov 2018
Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
HSMN NewsFeed - 5 Sep 2018
Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer
Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer
HSMN NewsFeed - 1 Aug 2018
Oncorus(R), Inc., Names Industry Veteran Ted Ashburn as new President and CEO
Oncorus(R), Inc., Names Industry Veteran Ted Ashburn as new President and CEO
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
HSMN NewsFeed - 20 Jun 2018
Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures
Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures
HSMN NewsFeed - 12 Jun 2018
Vergent Bioscience Raises $8.7 Million in Series A Financing Led by Spring Mountain Capital
Vergent Bioscience Raises $8.7 Million in Series A Financing Led by Spring Mountain Capital
HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 10 May 2018
Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
HSMN NewsFeed - 3 Apr 2018
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
HSMN NewsFeed - 15 Feb 2018
Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning
Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning
HSMN NewsFeed - 26 Jan 2018
Gamma Knife Radiosurgery Hits Half-century Mark With Over a Million Patients Treated
Gamma Knife Radiosurgery Hits Half-century Mark With Over a Million Patients Treated
HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
HSMN NewsFeed - 30 Nov 2017
Epic Sciences Launches Metastatic Breast Cancer Circulating Tumor Cell Panel
Epic Sciences Launches Metastatic Breast Cancer Circulating Tumor Cell Panel
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 21 Jul 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
HSMN NewsFeed - 20 Jul 2017
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
HSMN NewsFeed - 13 Jul 2017
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
HSMN NewsFeed - 10 Jul 2017
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
HSMN NewsFeed - 29 Mar 2017
Tyme Technologies Announces Two New Board of Director Appointments -- David Carberry and James Biehl
Tyme Technologies Announces Two New Board of Director Appointments -- David Carberry and James Biehl
HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 6 Jan 2017
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 8 Dec 2016
First Cancer Patients in the World Treated with the Smart, New Accuray Radixact(TM) System
First Cancer Patients in the World Treated with the Smart, New Accuray Radixact(TM) System
HSMN NewsFeed - 14 Nov 2016
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
HSMN NewsFeed - 19 Oct 2016
First Patient in Malaysia Receives TheraSphere(TM) Radioembolization Therapy
First Patient in Malaysia Receives TheraSphere(TM) Radioembolization Therapy
HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
HSMN NewsFeed - 19 Jul 2016
TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer
TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer
HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
HSMN NewsFeed - 3 Jun 2016
Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
HSMN NewsFeed - 1 Jun 2016
Elekta’s Leksell Gamma Knife Icon Cleared for Use in Japan and United States
Elekta’s Leksell Gamma Knife Icon Cleared for Use in Japan and United States
HSMN NewsFeed - 19 May 2016
Decipher Prostate Cancer Test Guides Timing of Postoperative Radiotherapy
Decipher Prostate Cancer Test Guides Timing of Postoperative Radiotherapy
HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
HSMN NewsFeed - 4 Feb 2016
GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy
GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy
HSMN NewsFeed - 29 Jan 2016
Helix BioPharma Corp. Announces Appointment of New Directors to the Board of Directors
Helix BioPharma Corp. Announces Appointment of New Directors to the Board of Directors
HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 2 Dec 2015
Surefire Medical Closes $15M Series C Financing Led by Tullis Health Investors
Surefire Medical Closes $15M Series C Financing Led by Tullis Health Investors
HSMN NewsFeed - 12 Nov 2015
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal(TM) (Thyroid microRNA Classifier)
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal(TM) (Thyroid microRNA Classifier)
HSMN NewsFeed - 28 Oct 2015
Turnstone Biologics Completes Series A Financing Led by Versant Ventures, Strengthens Management Team
Turnstone Biologics Completes Series A Financing Led by Versant Ventures, Strengthens Management Team
HSMN NewsFeed - 15 Oct 2015
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
HSMN NewsFeed - 30 Sep 2015
J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors
J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors
HSMN NewsFeed - 18 Aug 2015
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
HSMN NewsFeed - 16 Jul 2015
Immunocore Secures $320 Million (£205 Million) in Europe's Largest Private Life Sciences Financing
Immunocore Secures $320 Million (£205 Million) in Europe's Largest Private Life Sciences Financing
HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
HSMN NewsFeed - 21 Apr 2015
IlluminOss Medical Appoints Amy Orlick Berman as Vice President of Clinical Affairs
IlluminOss Medical Appoints Amy Orlick Berman as Vice President of Clinical Affairs
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 18 Mar 2015
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
HSMN NewsFeed - 23 Dec 2014
Personalized Cancer Vaccine Moves to Phase IIb Trial at Leading U.S. Cancer Hospitals
Personalized Cancer Vaccine Moves to Phase IIb Trial at Leading U.S. Cancer Hospitals
HSMN NewsFeed - 17 Dec 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
HSMN NewsFeed - 27 Aug 2014
Brainlab: First Patient Treatment with Revolutionary New Radiosurgery Software for Multiple Brain Metastases
Brainlab: First Patient Treatment with Revolutionary New Radiosurgery Software for Multiple Brain Metastases
HSMN NewsFeed - 21 Aug 2014
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
HSMN NewsFeed - 21 May 2014
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
HSMN NewsFeed - 31 Mar 2014
New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer
New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer
HSMN NewsFeed - 19 Mar 2014
IsoRay Announces World's First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor
IsoRay Announces World's First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor
HSMN NewsFeed - 5 Mar 2014
Leading Cancer Center in Portugal Becomes First in World to Offer Edge(TM) Radiosurgery
Leading Cancer Center in Portugal Becomes First in World to Offer Edge(TM) Radiosurgery
HSMN NewsFeed - 19 Feb 2014
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
HSMN NewsFeed - 18 Feb 2014
Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 17 Dec 2013
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
HSMN NewsFeed - 4 Dec 2013
Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
HSMN NewsFeed - 20 Nov 2013
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla(R) in the European Union
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla(R) in the European Union
HSMN NewsFeed - 9 Oct 2013
DFINE Announces First Commercial Cases with STAR(TM) Tumor Ablation System in Europe
DFINE Announces First Commercial Cases with STAR(TM) Tumor Ablation System in Europe
HSMN NewsFeed - 4 Oct 2013
MetaStat's MetaSite Breast(TM) Diagnostic Assay Predicts Metastasis in Breast Cancer Study
MetaStat's MetaSite Breast(TM) Diagnostic Assay Predicts Metastasis in Breast Cancer Study
HSMN NewsFeed - 1 Oct 2013
First urine-based cancer mutation monitoring test available from Trovagene
First urine-based cancer mutation monitoring test available from Trovagene
HSMN NewsFeed - 30 Sep 2013
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
HSMN NewsFeed - 17 Sep 2013
Dendreon Announces Marketing Authorization for PROVENGE(R) in the European Union
Dendreon Announces Marketing Authorization for PROVENGE(R) in the European Union
HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Additional items found! 500
Members Archive contains
500 additional stories matching:
MetaStat
(Password required)
MetaStat
(Password required)
